JP2021520832A5 - - Google Patents
Info
- Publication number
- JP2021520832A5 JP2021520832A5 JP2020556869A JP2020556869A JP2021520832A5 JP 2021520832 A5 JP2021520832 A5 JP 2021520832A5 JP 2020556869 A JP2020556869 A JP 2020556869A JP 2020556869 A JP2020556869 A JP 2020556869A JP 2021520832 A5 JP2021520832 A5 JP 2021520832A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- acid sequence
- binding site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024003062A JP2024056687A (ja) | 2018-04-16 | 2024-01-12 | キレート化された放射性核種に対する抗体 |
| JP2025244101A JP2026062683A (ja) | 2018-04-16 | 2025-12-10 | キレート化された放射性核種に対する抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658468P | 2018-04-16 | 2018-04-16 | |
| US62/658,468 | 2018-04-16 | ||
| PCT/EP2019/059856 WO2019201959A1 (en) | 2018-04-16 | 2019-04-16 | Antibodies for chelated radionuclides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024003062A Division JP2024056687A (ja) | 2018-04-16 | 2024-01-12 | キレート化された放射性核種に対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520832A JP2021520832A (ja) | 2021-08-26 |
| JP2021520832A5 true JP2021520832A5 (https=) | 2022-04-26 |
| JP7475283B2 JP7475283B2 (ja) | 2024-04-26 |
Family
ID=66476592
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556869A Active JP7475283B2 (ja) | 2018-04-16 | 2019-04-16 | キレート化された放射性核種に対する抗体 |
| JP2024003062A Withdrawn JP2024056687A (ja) | 2018-04-16 | 2024-01-12 | キレート化された放射性核種に対する抗体 |
| JP2025244101A Pending JP2026062683A (ja) | 2018-04-16 | 2025-12-10 | キレート化された放射性核種に対する抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024003062A Withdrawn JP2024056687A (ja) | 2018-04-16 | 2024-01-12 | キレート化された放射性核種に対する抗体 |
| JP2025244101A Pending JP2026062683A (ja) | 2018-04-16 | 2025-12-10 | キレート化された放射性核種に対する抗体 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20220389116A1 (https=) |
| EP (2) | EP3781200B1 (https=) |
| JP (3) | JP7475283B2 (https=) |
| KR (1) | KR102884852B1 (https=) |
| CN (1) | CN112261952A (https=) |
| AR (1) | AR115053A1 (https=) |
| AU (1) | AU2019254537B2 (https=) |
| BR (1) | BR112020021061A2 (https=) |
| CA (1) | CA3096338A1 (https=) |
| CL (1) | CL2020002680A1 (https=) |
| CR (1) | CR20200548A (https=) |
| DK (1) | DK3781200T3 (https=) |
| ES (1) | ES2985352T3 (https=) |
| FI (1) | FI3781200T3 (https=) |
| HR (1) | HRP20241013T1 (https=) |
| HU (1) | HUE067622T2 (https=) |
| IL (1) | IL277575B2 (https=) |
| LT (1) | LT3781200T (https=) |
| MA (1) | MA52545B1 (https=) |
| MX (1) | MX2020010954A (https=) |
| MY (1) | MY207044A (https=) |
| PE (1) | PE20210442A1 (https=) |
| PL (1) | PL3781200T3 (https=) |
| PT (1) | PT3781200T (https=) |
| RS (1) | RS65753B1 (https=) |
| SG (1) | SG11202010066TA (https=) |
| SI (1) | SI3781200T1 (https=) |
| TW (1) | TWI874314B (https=) |
| UA (1) | UA130541C2 (https=) |
| WO (1) | WO2019201959A1 (https=) |
| ZA (1) | ZA202006121B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| AR119382A1 (es) * | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CR20230076A (es) * | 2020-07-10 | 2023-03-13 | Hoffmann La Roche | Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células |
| JP2024504931A (ja) | 2021-01-12 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体 |
| CA3204291A1 (en) | 2021-01-13 | 2022-07-21 | F. Hoffmann-La Roche Ag | Combination therapy |
| CN116744981A (zh) * | 2021-01-13 | 2023-09-12 | 豪夫迈·罗氏有限公司 | 组合疗法 |
| JP2024546810A (ja) | 2021-12-15 | 2024-12-26 | ワイ－マブス セラピューティクス， インコーポレイテッド | 多量体化が低減されているｓｃＦｖ及び抗体 |
| WO2024099526A1 (en) | 2022-11-08 | 2024-05-16 | Y-Mabs Therapeutics, Inc. | Bispecific antibody compounds |
| WO2025176614A1 (en) | 2024-02-20 | 2025-08-28 | F. Hoffmann-La Roche Ag | Novel pre-targeting antibodies and uses thereof |
| WO2026041568A1 (en) | 2024-08-20 | 2026-02-26 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and dotam |
| WO2026082710A1 (en) | 2024-10-16 | 2026-04-23 | F. Hoffmann-La Roche Ag | Small molecule-inducible recombinant receptors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201608192SA (en) * | 2014-04-11 | 2016-10-28 | Medimmune Llc | Bispecific her2 antibodies |
| ES2809598T3 (es) | 2014-12-23 | 2021-03-04 | Inst Nat Sante Rech Med | Composiciones farmacéuticas para el tratamiento de superinfecciones bacterianas post-influenza |
| EP3253799B1 (en) * | 2015-02-05 | 2020-12-02 | Molecular Templates, Inc. | Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
| CN107847584B (zh) * | 2015-02-09 | 2022-01-25 | 纪念斯隆凯特琳癌症中心 | 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途 |
| PE20180484A1 (es) * | 2015-10-02 | 2018-03-07 | Hoffmann La Roche | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
| CN112638416A (zh) | 2018-04-16 | 2021-04-09 | 奥兰诺医药公司 | 针对螯合的放射性核素的抗体和清除剂 |
-
2019
- 2019-04-16 TW TW108113285A patent/TWI874314B/zh active
- 2019-04-16 CA CA3096338A patent/CA3096338A1/en active Pending
- 2019-04-16 BR BR112020021061-7A patent/BR112020021061A2/pt unknown
- 2019-04-16 CR CR20200548A patent/CR20200548A/es unknown
- 2019-04-16 WO PCT/EP2019/059856 patent/WO2019201959A1/en not_active Ceased
- 2019-04-16 PL PL19723014.7T patent/PL3781200T3/pl unknown
- 2019-04-16 EP EP19723014.7A patent/EP3781200B1/en active Active
- 2019-04-16 KR KR1020207032824A patent/KR102884852B1/ko active Active
- 2019-04-16 HR HRP20241013TT patent/HRP20241013T1/hr unknown
- 2019-04-16 CN CN201980038709.1A patent/CN112261952A/zh active Pending
- 2019-04-16 SG SG11202010066TA patent/SG11202010066TA/en unknown
- 2019-04-16 AR ARP190101005A patent/AR115053A1/es unknown
- 2019-04-16 EP EP24169799.4A patent/EP4406607A3/en active Pending
- 2019-04-16 FI FIEP19723014.7T patent/FI3781200T3/fi active
- 2019-04-16 SI SI201930792T patent/SI3781200T1/sl unknown
- 2019-04-16 RS RS20240810A patent/RS65753B1/sr unknown
- 2019-04-16 LT LTEPPCT/EP2019/059856T patent/LT3781200T/lt unknown
- 2019-04-16 PE PE2020001551A patent/PE20210442A1/es unknown
- 2019-04-16 IL IL277575A patent/IL277575B2/en unknown
- 2019-04-16 JP JP2020556869A patent/JP7475283B2/ja active Active
- 2019-04-16 US US17/048,073 patent/US20220389116A1/en not_active Abandoned
- 2019-04-16 PT PT197230147T patent/PT3781200T/pt unknown
- 2019-04-16 DK DK19723014.7T patent/DK3781200T3/da active
- 2019-04-16 HU HUE19723014A patent/HUE067622T2/hu unknown
- 2019-04-16 MY MYPI2020005339A patent/MY207044A/en unknown
- 2019-04-16 ES ES19723014T patent/ES2985352T3/es active Active
- 2019-04-16 AU AU2019254537A patent/AU2019254537B2/en active Active
- 2019-04-16 MX MX2020010954A patent/MX2020010954A/es unknown
- 2019-04-16 MA MA52545A patent/MA52545B1/fr unknown
- 2019-04-16 UA UAA202007212A patent/UA130541C2/uk unknown
-
2020
- 2020-10-02 ZA ZA2020/06121A patent/ZA202006121B/en unknown
- 2020-10-16 CL CL2020002680A patent/CL2020002680A1/es unknown
-
2024
- 2024-01-12 JP JP2024003062A patent/JP2024056687A/ja not_active Withdrawn
-
2025
- 2025-09-18 US US19/333,297 patent/US20260015436A1/en active Pending
- 2025-12-10 JP JP2025244101A patent/JP2026062683A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021520832A5 (https=) | ||
| FI3781200T3 (fi) | Kelatoituneiden radionuklidien vasta-aineita | |
| JP2024056687A5 (https=) | ||
| JP2021503455A5 (https=) | ||
| JP2023539245A5 (https=) | ||
| JP2021508469A5 (https=) | ||
| JP2023538945A5 (https=) | ||
| JP2023509448A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| HRP20201928T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 | |
| JP2023551027A5 (https=) | ||
| JP2020508655A5 (https=) | ||
| JP2021510521A5 (https=) | ||
| JP2018510636A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| JP2021533159A5 (https=) | ||
| JP2018526981A5 (https=) | ||
| HRP20120759T1 (hr) | Bispecifična veziva specifična između vrsta | |
| RU2018102803A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2010524435A5 (https=) | ||
| JP2022512234A5 (https=) | ||
| JP2021522347A5 (https=) | ||
| JP2020515277A5 (https=) | ||
| JP2024520188A5 (https=) | ||
| JP2022540610A5 (https=) |